1. Home
  2. BLBD vs ORKA Comparison

BLBD vs ORKA Comparison

Compare BLBD & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Bird Corporation

BLBD

Blue Bird Corporation

HOLD

Current Price

$54.82

Market Cap

1.7B

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$32.93

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLBD
ORKA
Founded
1927
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BLBD
ORKA
Price
$54.82
$32.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$67.20
$52.70
AVG Volume (30 Days)
470.0K
291.8K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
22.78
N/A
EPS
0.94
N/A
Revenue
$1,480,099,000.00
N/A
Revenue This Year
$6.07
N/A
Revenue Next Year
$6.37
N/A
P/E Ratio
$60.12
N/A
Revenue Growth
9.87
N/A
52 Week Low
$30.15
$5.49
52 Week High
$62.90
$36.53

Technical Indicators

Market Signals
Indicator
BLBD
ORKA
Relative Strength Index (RSI) 44.34 48.54
Support Level $54.23 $25.65
Resistance Level $58.57 $36.52
Average True Range (ATR) 2.52 1.94
MACD -0.81 -0.11
Stochastic Oscillator 8.18 33.88

Price Performance

Historical Comparison
BLBD
ORKA

About BLBD Blue Bird Corporation

Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: